BSFAF (BSF Enterprise) Buyback Yield %: -6.51 (As of Jul. 08, 2026)


What is BSF Enterprise Buyback Yield %?

BSF Enterprise BSFAF Buyback Yield % is -6.51 as of Jul. 08, 2026. The stock has 3 warning signs investors should review. Among 740 Biotechnology companies, BSF Enterprise ranks better than 50.41% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BSF Enterprise's current buyback yield was -6.51%.

BSF Enterprise Buyback Yield % Historical Data

* Premium members only.

The historical data trend for BSF Enterprise's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BSF Enterprise Buyback Yield % Chart

BSF Enterprise Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Buyback Yield %
Get a 7-Day Free Trial 0.00 0.00 -17.44 0.00 -19.32

BSF Enterprise Semi-Annual Data
Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.42 0.00 -26.96 -15.39 -11.06

BSFAF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, BSF Enterprise's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BSF Enterprise Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BSF Enterprise's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BSF Enterprise's Buyback Yield % falls into.


BSF Enterprise Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BSF Enterprise's Buyback Yield for the fiscal year that ended in Sep. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.868) / 4.49309
=-19.32%

BSF Enterprise's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0.192) / 2.053984
=-9.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -6.51 mean?
BSF Enterprise (BSFAF) has a Buyback Yield % of -6.51 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BSF Enterprise and its competitors. According to the industry distribution chart, BSF Enterprise ranks #367 out of 740 companies in the Biotechnology industry, placing it in the top 49.6%.
Is BSF Enterprise's Buyback Yield % too high?
BSF Enterprise's current Buyback Yield % is -6.51. Based on the distribution chart, BSF Enterprise ranks #367 out of 740 companies in the Biotechnology industry, which is above the industry midpoint.
How does BSF Enterprise's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BSF Enterprise ranks #367 out of 740 companies for Buyback Yield %. This puts BSF Enterprise in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BSF Enterprise and its competitors. BSF Enterprise's current Buyback Yield % is -6.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BSF Enterprise stock overvalued right now?
BSF Enterprise (BSFAF) has a current Buyback Yield % of -6.51. The current Buyback Yield % is -6.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BSF Enterprise (BSFAF), the current Buyback Yield % is -6.51 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BSF Enterprise Business Description

Other Exchanges BSFA:UK
Address 2 Portman Street, London, GBR, W1H 6DU
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.